Researchers are rapidly investigating retatrutide, here a innovative treatment developed by Eli Lilly, as a significant advance in physique management. Unlike many existing approaches, retatrutide is a twin-action agonist targeting equally GLP-1 and GIP, chemicals that influence appetite and glucose